Inhaler
Latest Astrazeneca AB Patents:
- Method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
- Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
- Dendrimer formulations
- GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
- PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS
FIG. 1 is a front perspective view from above and to one side of an inhaler showing our new design, shown in open configuration;
FIG. 2 is a rear perspective view from above and the other side of the inhaler, shown in open configuration;
FIG. 3 is a side elevational view thereof, the opposite side elevational view being a mirror image thereto;
FIG. 4 is a front elevational view thereof;
FIG. 5 is a top plan view thereof;
FIG. 6 is a bottom plan view thereof;
FIG. 7 is a rear elevational view thereof;
FIG. 8 is a front perspective view from above and to one side of the inhaler, shown in closed configuration;
FIG. 9 is a rear perspective view from above and the other side the inhaler, shown in closed configuration;
FIG. 10 is a side elevational view thereof, the opposite side elevational view being a mirror image thereto;
FIG. 11 is a front elevational view thereof;
FIG. 12 is a top plan view thereof;
FIG. 13 is a bottom plan view thereof; and,
FIG. 14 is a rear elevational view thereof.
Claims
The ornamental design for an “inhaler,” as shown and described.
Type: Grant
Filed: Sep 27, 1999
Date of Patent: Jun 26, 2001
Assignee: Astrazeneca AB (Sodertalje)
Inventors: Malin Andersson (Stockholm), Maria Benktzon (Sollentuna), Lennart Brunnberg (Tyreso), Sven-Eric Juhlin (Stockholm)
Primary Examiner: Ian Simmons
Attorney, Agent or Law Firm: Nixon & Vanderhye
Application Number: 29/111,474
International Classification: 2902;